Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cells pulsed with AT-2-inactivated HIV
- Development stage
- Phase 2
- Lead developer
- University of Sao Paulo General Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intradermal
01
Overview
This experimental therapeutic vaccine approach, developed by the University of São Paulo General Hospital, is an autologous cellular immunotherapy designed for the treatment of HIV infection. The therapy involves harvesting a patient's own dendritic cells (DCs) and pulsing them ex vivo with autologous HIV that has been chemically inactivated using Aldrithiol-2 (AT-2). AT-2 is a chemical agent that eliminates viral infectivity while preserving the structural integrity of viral envelope proteins, which are critical for immune recognition. These loaded dendritic cells are then reinfused into the patient to stimulate or enhance HIV-specific cellular immune responses, particularly targeting T-cell activation. The approach represents a personalized medicine strategy aimed at controlling viral load in treatment-naive, chronically infected HIV patients.
- Other names
- Anti-HIV cellular therapy based on dendritic cells pulsed with chemically inactivated virusAT-2 inactivated HIV-pulsed dendritic cellsAT2 inactivated HIV-pulsed dendritic cellsAT 2 inactivated HIV-pulsed dendritic cellsAutologous dendritic cells pulsed with Aldrithiol-2-inactivated HIV
Beyond the preview
Go deeper on autologous dendritic cells pulsed with AT-2-inactivated HIV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cells pulsed with AT-2-inactivated HIV.